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A safe, inexpensive, noninfectious substitute for red
blood cells has long been sought. Despite tremendous
advances in blood banking, the logistics of collecting,
transporting, and storing human red blood cells contin-
ues to create infection and shortage problems. The two
basic types of blood substitutes currently under devel-
opment are hemoglobin based and fluorocarbon based.
Although they each transport oxygen differently, the
basic advantages and limitations are the same. Blood
substitute advantages include the unique capacity for
room temperature storage, noninfectivity, adequate
supply, and low toxicity. Restrictions include limited
dosing in the acute period, limited intravascular half-life
and, for the fluorocarbons, a requirement for a high
PaO2. In addition, there remain questions about the
relationship of nitric oxide metabolism to hypertension
in hemoglobin solutions. Early clinical and laboratory
trials have shown that both types of solutions are
effective oxygen-delivery agents, with acceptable side-
effect profiles. Clinical trials are currently underway to
determine the safety and efficacy of these solutions in
patients undergoing cardiopulmonary bypass.
Copyright&copy; 1998 by W B. SaundersCompany.
T he War Department (now the DepartmentJL of Defense) began an earnest search for a
blood substitute before World War II. It was
recognized that nearly one-third of all battlefield
deaths occurred because of hemorrhage alone.
The logistics of collecting, storing, transporting,
and cross-matching allogeneic blood under
battlefield conditions meant that many soldiers
died of eminently treatable wounds. The War
Department originally sought a hemoglobin solu-
tion that could be stored indefinitely at room
temperature, preferably in a dessicated form,
and be transfused without the need for cross-
matching. Nearly 60 years later, blood substitutes
appear to be within 2 to 5 years of commercial
production. Although the chief reasons for the
desirability of these solutions have changed over
the years, the most prominent current impetus
for developing these substitutes is the risk of
allogeneic transfusion. Although safer than at
any time in the past, there are risks inherent to
the transfusion of allogeneic bloody 1
These risks of allogeneic transfusion are pri-
marily immunologic and infectious.2,3 Immuno-
logic risks range from hemolytic reaction to
incompatible blood (the most common cause of
fatality caused by blood transfusion and most
often caused by clerical error)3,4 to the poorly
understood immunomodulation associated with
allogeneic bloody7 Infectious risks include bacte-
rial, rickettsial, and viral vectors, but patients are
generally most concerned with the risk of human
immunodeficiency virus transmission. The cur-
rent estimated risks of allogeneic blood transfu-
sion are listed in Table 1.
Awareness of the risks of allogeneic blood
transfusion have led to a re-evaluation of blood
transfusion practices. The most viable tech-
niques for limiting the use of allogeneic blood
are: (1) increased tolerance for anemia, (2) the
use of autologous donation, (3) pharmacologic
means of decreasing blood loss, and (4) the
possible use of blood substitutes. A complete
discussion of these four techniques is beyond
the scope of this review, but a brief discussion of
the limits of anemia is required to understand
the potential niche for so-called blood substi-
tutes.
Physiologic Limits of Anemia
Oxygen Delivery During,Anemia
Several studies suggest that mammals have a
large reserve of red blood cells. Normovolemic
anemia is well tolerated when there is adequate
cardiac reserve to compensate for decreased
oxygen-carrying capacity by increased blood flow.
Laboratory baboons, dogs, and pigs tolerate
acute normovolemic hemodilution to hemato-
crits as low as 4% to 7%. The primary compensa-
tion involves increased stroke volume down to a
hematocrit of approximately 20% and increased
heart rate at lower hematocrits. This compensa-
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Table 1. Estimate of the Current Risk of Blood
Transfusion (United States, 1996)
tory increase in cardiac output maintains tissue
oxygen delivery despite a decreasing arterial
oxygen content. This increased cardiac output,
however, increases myocardial oxygen demand
at the same time that myocardial oxygen delivery
is reduced. In the myocardium, as in the rest of
the body, increased oxygen delivery must occur
through increased blood flow. In the setting of
cardiac surgery, with patients in whom coronary
artery flow is already significantly compromised,
anemia may result in ischemia.8 Defining the
limits of anemia in cardiac surgical patients has
not been simple.
The majority of studies that attempt to define
the limits of anemia in the setting of coronary
artery disease (CAD) involve laboratory animals.
In a series of canine experiments, Spahn et al
showed that: (1) cardiac failure caused by ane-
mia occurs at a higher hematocrit in dogs with
coronary stenosis than in dogs without stenosis,
(2) the lowest mean hematocrit tolerated with-
out signs of ischemia is 21 % in dogs with stenosis
versus 14% in dogs without; and (3) dogs with
multivessel CAD suffer cardiac failure caused by
anemia at a higher hematocrit than dogs with
single-vessel disease.9-11
Studies of the limits of anemia in humans with
CAD are less common. Herregods et a112 per-
formed hemodilution in patients with left main
disease and found no signs of ischemia at a
hematocrit of 30%. Jalonen et a113 performed
hemodilution in 66 patients undergoing coro-
nary artery bypass surgery and found no evi-
dence of ischemia to hematocrits of 28%. At
present, there is no evidence that hemodilution
to hematocrits less than 28% is without risk.
Nelson et a114 presented postoperative data with
respect to myocardial ischemia and morbidity in
27 high-risk patients who underwent vascular
surgery. The study noted a significant increase in
postoperative myocardial ischemia and morbid-
ity (cardiogenic pulmonary edema, myocardial
infarction, and cardiac death) when the hemato-
crit decreased to 28% or less. They concluded
these data suggest that hematocrits less than 28%
may have a role in postoperative ischemia and
cardiac morbidity.
Despite the plethora of evidence that healthy
laboratory animals can tolerate hematocrits less
than 10%, evidence to date using normothermic
human subjects would support maintaining a
hematocrit of greater than 28% in patients with
CAD or providing additional oxygen-carrying
capacity above and beyond that of the remaining
red cells. It is hoped that the addition of oxygen-
carrying colloids to provide oxygen delivery
reserve during acute normovolemic hemodilu-
tion will permit widespread use of this technique
during surgery and thereby decrease the use of
allogeneic blood transfusions. 15,16 There are cur-
rently two primary types of blood substitutes
under development: the hemoglobin-based solu-
tions and the fluorocarbon solutions (Table 2).
In truth, neither of these solutions is a blood
substitute. Mammalian blood performs a myriad
of functions and, as Ambersonl7 wrote in his
1937 review of blood substitutes, blood
... is the most complicated fluid to be found in the
~orM o/~ &MMg’ o~mM~M. Com~oMK<~ o/~ a <~oz~Mw rld f living rganisms. pounded f d en
essential ingredients sustaining a multiplicity of activi-
ties, the fluid pathway for a variety of chemical and
hormonal integrations of function, the source of food
and oxygen for every tissue, it defies laboratory~~ .~g)?M yb ~~r ~mM~  ~ c!~~ / ~’o~~07’
synthesis. At the very beginning we must recognize that
there is no complete substitute for blood,. 17 7
In essence, all the current blood substitutes
under development should be defined as oxygen-
carrying colloids, and because oxygen transport
differs among these compounds, a brief review of
normal oxygen transport is in order.
Basics of Oxygen Transport
Oxygenation is adequate when oxygen is being
supplied to the tissues at a sufficient rate to
maintain aerobic metabolism. Arterial oxygen
content is defined as the volume of oxygen (in
milliliters) carried in 100 mL of blood.
in which Ca02 = arterial oxygen content in
milliliters per 100 mL (also called vol %), Hb =
hemoglobin concentration in grams per decili-
ter, 1.37 = the volume of oxygen (in milliliters)
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Table 2. Current Oxygen-Carrying Colloids Under Development
NOTE. Baxter, Deerfield, IL; Biopure, Boston, MA; Northfield, Evanston, IL; Somatogen, Boulder, CO, Hemasol, Ontario,
Canada, Enzol, Piscataway, NJ.
Abbreviations: Hb, hemoglobin; PEG, polyethyleneglycol; P50, the arterial oxygen partial pressure at which 50% of the
hemoglobin is saturated, 50% is desaturated.
carried by 1 g of fully saturated hemoglobin,
Sa02 = fractional hemoglobin saturation (%
Hb02/total Hb), 0.0034 = the solubility coeffi-
cient of oxygen in plasma (milliliters of oxygen
per 100 mL of plasma per millimeters of mer-
cury), and Pa02 = the arterial oxygen tension in
millimeters of mercury.
With a normal 15 g of hemoglobin and nor-
mal arterial Pa02 and Sa02 values of 90 mmHg
and 97%, respectively, an arterial oxygen content
of 20 vol % is obtained.
Equation 1 shows that the vast proportion of
oxygen is carried by the hemoglobin; relatively
little is dissolved in the plasma because of water’s
low solubility for oxygen. Conversely, once the
hemoglobin is fully saturated at a P02 of approxi-
mately 90 mmHg, as oxygen tension increases,
no oxygen is added to the hemoglobin phase
while oxygen continues to dissolve in the water
phase. If a patient were to breathe hyper-
baric oxygen and have a Pa02 of 1,500 mmHg,
the dissolved oxygen content in the plasma
would be approximately 5 vol %, thereby contrib-
uting significantly to the oxygen content
(Fig 1 ) .
The overall flow rate of oxygen to the tissues is
the arterial oxygen content times the - cardiac
output. At a cardiac output of 5 L/min, a nor-
mal oxygen delivery of 1,000 mL of oxygen/
min is obtained. A normal cardiac index (car-
diac index = cardiac output/body surface area
[m2] ) is 3 L/min/m2 (range, 2.7 to 3.4 L/min/
m2).
The tissues consume an average of 5 mL of
oxygen from every 100 mL of blood flow, with
75% of the oxygen remaining in the venous
blood. The oxygen consumption of the body can
be calculated as follows:
Oxygen consumption index = V02 (Ca02 -
Cv02 ) X cardiac index.
The hemoglobin in blood normally unloads 5
vol % of oxygen as it passes through the tissues,
as shown in Figure 1. The dissolved oxygen in the
plasma contributes little under these circum-
stances, but if the P02 were increased to 1,500
mmHg, a patient could theoretically survive on
the oxygen dissolved in the plasma having a
mixed venous hemoglobin saturation of 100%.
In this situation, although the plasma only car-
ries a little more than 5 vol % because it is
released to the tissues in a direct proportion to
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Figure 1. Oxygen content is plotted versus P02 for
blood with hematocrits of 45% and 12%. At 500
mmHg, blood with hematocrit (HCT) of 45% has an
arterial content of 21 % and a venous content of 16%,
but the venous P02 is in the range of 50 mmHg. A 20%
PFC emulsion will have an arterial content of only 7
vol % but if this same 5 vol % is extracted, the mixed
venous P09 will be approximately 150 mmHg. Con-
tent lines drawn for hemoglobin solutions would be
similar to blood.
the oxygen tension, nearly all the oxygen is
extracted (Fig 1). The understanding of these
two methods of oxygen transport (hemoglobin
carriage v dissolved carriage) becomes impor-
tant when the two types of blood substitute are
discussed and compared.
Calculation of 02 Content With
Oxygen-Carrying Colloids
Perjluorochemical oxygen content. As shown
in Figure 1, perfluorochemicals (PFCS) carry
oxygen by direct solubility, as does plasma.
The following oxygen content equation has a
third term that represents the PFC contribu-
tion :
in which Fct = fluorocrit, fraction of PFC in
blood analogous to hematocrit.
The solubility factor in the third term (0.057) *
is nearly 20 times that of the solubility factor
for oxygen in plasma (0.0034) .18 The PFCs con-
tribution is a direct function of the Pa02 and
the volume of PFC present, the fluorocrit, or
Fct.
Hemoglobin solutions: oxygen content. If the he-
moglobin solution (either stroma free or micro-
encapsulated) has the same P50 as blood (27
mmHg), there is no difference in the oxygen
content equation. If the P50 of the hemoglobin
solution is significantly different from that of
blood, the content will vary depending on the
concentration of the hemoglobin solution and
its saturation. That is, the oxygen tension will be
constant and the saturations will vary, as shown:
in which FHb = concentration of hemoglobin
solution in blood in grams per deciliter and
FSaOg = saturation of the FHb. The P50s of
hemoglobin-based oxygen carriers, as listed in
Table 2, are similar to that of normal blood.
Microcirculation and Oxygen-Carrying
Colloids
These oxygen-carrying colloids differ in another
way from red cells, and that is in their size range.
The hemoglobin solutions range from 68,000 to
500,000 RDA and the fluorochemical emulsion
particles are in the range of 0.2 pm. This size
range is within that of many of the plasma
proteins. These particles, therefore, can be ex-
pected to participate in the extravascular circula-
tion as do plasma proteins. Animal data indicate
that these oxygen-carrying colloids leave the
intravascular space and rejoin it through the
lymphatic circulation (E.E. Jacobs, Jr, personal
communication, May 1997). This raises interest-
ing questions about the ability of these colloids
to provide oxygen delivery to the extravascular
space. In addition, work in microcirculation has
shown that capillaries can open and close to red
cell flow, but that plasma flow continues even
when red cells are not traversing the capillary.
Again, because the oxygen-carrying colloids travel
*T’~~:C~T’ 0.<?37 M ~ ~O/MM~ 0/’ Os !K PFC M!MM~ z*The factor .057 is the solubility of 2 in minus the
solubility of 02 in plasma. This is required because as PFC is added
to the plasma, there is less plasma available to carry O2.
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in the plasma space, they can provide oxygen
delivery to tissues even though red cells are not
present in the capillaries. It has been speculated
that the oxygen-carrying colloids will provide
enhanced tissue oxygen delivery, especially in
tissues in which red cell flow is limited.
PFC Emulsions
In 1965, Clark and Gollanl9 performed an inge-
nious experiment that spawned the develop-
ment of an entirely new concept in oxygen
transport. They were experimenting with a new
series of compounds known as PFCs because of
their unique capacity as chemically inert liquids
with extremely high solubilities for gases. These
PFCs were composed of 8 to 10 completely
fluorinated carbon structures, which made them
inert liquids with a density nearly twice that of
water. Because their solubility for oxygen was
nearly 20 times that of water, these investigators
questioned whether an animal could survive
breathing this liquid equilibrated with one atmo-
sphere of oxygen. They submerged a rat in
equilibrated liquid for 30 minutes and found the
animal suffered no apparent harm. Because
these liquids are completely immiscible in water,
an intravenous injection is immediately lethal
because it would form a liquid embolus.
In 1968, Gehes et a12° produced a microemul-
sion (particle size, 0.1 pm) of a PFC in normal
saline. They conducted a complete exchange
transfusion with a rat that maintained survival
breathing 100% oxygen with a hematocrit of
zero. Because of the inertness of these com-
pounds, they are not metabolized but are cleared
from the vascular space by the reticuloendothe-
lial (RE) system and ultimately collect in the liver
and spleen. The PFC leaves the body slowly, as
vapor in the respiratory gas. Because the PFCs
transport oxygen by simple solubility, the amount
of oxygen carried is directly proportional to the
percent of the PFC in the blood stream and the
Pa02.
Figure 1 shows the carrying capacity of a
theoretical PFC emulsion with a 20% and a 90%
concentration of PFC. Note that the amount of
oxygen carried by a PFC emulsion is substantially
less than that of blood with a normal hematocrit.
Because the PFC carries oxygen by direct solubil-
ity, it also releases it in a direct proportion to the
P02, unlike the cooperative binding effect of
hemoglobin. From the preceding description of
oxygen transport, the potential contribution of
PFCs to oxygen transport may be assessed by
looking at mixed venous values of P02 and the
quantity of oxygen consumed by the tissue
( Ca02 - Cv°2 = 5 vol 1 %). If a PVOz of 40
mmHg and an oxygen extraction of 5 vol % are
assumed, a bloodless animal could survive with
fluorocrits of 10%, 20%, and 50% with Pa02
values of 800, 650, and 250 mmHg, respectively.
From these calculations, it would appear that a
patient could survive with a PFC emulsion with-
out red blood cells. Practically, this would be
difficult because the emulsion is cleared from
the vascular space within 24 hours. Also, because
of the long tissue half-time of a PFC in the body
(months to years, depending on the PFC com-
pound), it would not be feasible to continuously
re-dose the patient.
The primary toxicities of these compounds
concern their potential effects on the RE system
as they are cleared. No long-term toxicities have
been noted, but there are concerns of an RE cell
blockade and potential effects on the liver be-
cause the RE system capacity may be over-
whelmed when PFCs are cleared from the vascu-
lar space.
The primary technical problem in producing
a clinically usable product was the development
of a stable emulsion that contained sufficient
PFC. In the late 1970s, the Green Cross Corpora-
tion (Osaka, Japan) developed a product called
Fluosol DA-20%, an emulsion composed of two
PFCs (perfluorodecalin and perfluorotripropyl-
amine) .18~2o The combination of two PFCs was
used to take advantage of the emulsion stability
of one PFC (perfluorodecalin) and the shorter
tissue half-life of the other (perfluorotripropyl-
amine). Even with this mixture, the solution only
contained 10% PFC (Fluosol DA-20% is 20% by
weight, 10% by volume). The surfactant used to
maintain this emulsion was pluronic F68, an
emulsifier that had been used in other medical
products. To maintain stability, the product also
required freezing until just before use. In the
early 1980s, clinical studies were initiated in
patients who refused blood transfusions, were
actively bleeding, and required surgery. In this
unique patient population, 20 mL/kg of body
weight of emulsion was transfused preoperatively
with a maximum of one additional dose postop-
eratively.21 The patients achieved a maximal
277
fluorocrit of just less than 3% with an intravascu-
lar half-life of approximately 19 hours. Subse-
quent studies confirmed the oxygen-carrying
contribution of the PFC but could not show a
beneficial effect on patient outcome.22 Another
problem with Fluosol DA-20% was the appear-
ance of an acute complement-mediated reaction
caused by the surfactant, which necessitated pre-
treatment with corticosteroids for all patients.
Despite these shortcomings, Fluosol DA-20%
is the only oxygen-carrying colloid to gain Food
and Drug Administration approval (approved
for intracoronary infusion in patients undergo-
ing angioplasty). Fluosol DA-20% improved myo-
cardial recovery in an isolated neonatal pig heart
model.23 A trial of Fluosol as adjunct reperfusion
therapy aimed at preventing reperfusion injury
for patients with acute myocardial infarction,
however, failed to show any decrease in infarct
size or improvement in myocardial function.24
The incidence of recurrent ischemia was de-
creased in patients receiving Fluosol. 24
Over the past few years, second-generation
PFC emulsions have been under development.
One of these uses the perfluorocarbon perfluo-
rooctylbromide.25 This PFC is unique in that it
has one bromine replacing a fluorine, making it
radiopaque. This emulsion, Oxygent (Alliance
Pharmaceuticals, San Diego, CA), contains 90%
PFC by weight, or 45 % by volume. It is emulsified
with lecithin and is stable at room temperature
for more than 6 years. Given the general limita-
tions of PFCs (that they require high inspired
oxygen and will have an intravascular half-life of
approximately 24 to 36 hours), animal and
clinical studies currently underway are investigat-
ing this product as an intraoperative oxygen
supplement used in conjunction with isovolemic
hemodilution. The hopes are this product will
supplement oxygen transport intraoperatively,
thereby lessening the need for blood transfu-
sions in the postoperative period. The ultimate
use of PFC emulsions in the perioperative period
has yet to be determined, although one pilot
study in surgical patients showed enhanced mixed
venous P02 in patients receiving a perfluorocar-
bon emulsion.26
Hemoglobin Solutions
As previously noted, numerous difficulties have
slowed the development of a hemoglobin-based
solution. The first problem is the renal toxicity
associated with impurities in the hemoglobin
solutions, predominantly from residual red cell
membranes (stroma). These problems were first
identified by Rabiner et al27 and research since
has been directed toward producing a stroma-
free hemoglobin solution. The second problem
is associated with the altered affinity of hemoglo-
bin for oxygen. When hemoglobin is removed
from a red blood cell, 2,3-diphosphoglycerate is
lost and the normal tetramer dissociates into two
a and 13 dimers, changing the oxygen affinity and
reducing the P50 from the normal of 26.7
mmHg to the range of 12 to 14 mmHg.28 The
hemoglobin, therefore, picks up oxygen very
aggressively but may never release it at the
normal oxygen tensions seen in the cardiovascu-
lar system. A third problem results from the
small size of the hemoglobin dimers. At 32,000
RDA, these dimers are small enough to be
diuresed by the kidney. Consequently, when
unmodified stroma-free hemoglobin solutions
are infused intravascularly, they pick up oxygen
and then act as an osmotic diuretic, ultimately
reducing the intravascular volume by causing the
patient to lose not only hemoglobin, but the
oxygen attached to it in the urine. This &dquo;red
mannitol&dquo; effect of the early hemoglobin solu-
tions was resolved by increasing the P50 and
increasing the molecular size. Cross-linking the
molecule with pyridoxal-5-phosphate or diaspi-
rin compounds has been successful in stabilizing
the tetramer and improving the P50 to near the
normal range.29 The effective size has been
further increased by either attaching the hemo-
globin molecule to another molecule of larger
size or by forming a hemoglobin polymer to
increase circulating lifetime.3° Again, as with
PFCS, the hemoglobin solutions are cleared from
the vascular space quickly, in a matter of 24 to 48
hours, depending on the dose.
The hemoglobin used in these solutions comes
from a variety of sources. The first is human
blood from volunteers, which may face the same
limited supply that blood banks now struggle
with. Bovine hemoglobin is more readily avail-
able, with a supply of nearly 1 million units a day
from meat production. Hemoglobin has also
been produced using recombinant technol-
ogy.30,31
Each of the hemoglobin solutions in clinical
trials currently should be considered a different
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drug, each with a unique pharmacokinetic and
pharmacodynamic profile. Each of the solutions
is derived from a different source, stabilized in a
different way (cross-linking v polymerization v
genetic mutation), has a different concentration,
and should be expected to show a different
side-effect profile. To date, there are insufficient
data in the literature to assess each of these
solutions adequately. Despite their differences,
each of the hemoglobin solutions must address
the following challenges: limited intravascular
half-life, hemodynamic alterations, and interfer-
ence with clinical laboratory testing.
Like the fluorochemical solutions, the hemo-
globin solutions are recognized by the body as an
abnormal physiologic event, and the RE system
scavenges the particles from the blood stream.
The effective life of the hemoglobin solutions is
about 24 to 48 hours, depending on the dose. 32
Therefore, these solutions will, like the PFCs,
find their greatest applicability in acute, limited
blood-loss situations, perhaps again associated
with an autologous hemodilution scheme during
surgery 15,16,33 Unlike the PFCS, however, hemo-
globin solutions may offer a solution to the
problem of limited intravascular retention. Ani-
mals that are hemodiluted to very low hemato-
crits and are then transfused with hemoglobin
solutions show a dramatic reticulocytosis that
exceeds that expected from exogenous erythro-
poietin. Beagles bled to a hematocrit of 5%
required only two doses of hemoglobin solution
over an 8-day period. By day 8, the average
hematocrit had returned to 15% because of
significant red blood cell production (E.E. Ja-
cobs, personal communication, May 1997).
All hemoglobin products also appear to have
some hemodynamic effect. As shown in Table 3,
all cause some degree of vasoconstriction, espe-
cially in the pulmonary vasculature. 34-38 At first
this was believed to be caused by contaminants,
but this effect is also seen with genetically de-
rived pure hemoglobin. It has recently been
discovered that this vasoconstrictive effect is
produced because of hemoglobin’s role in nitric-
oxide equilibrium. 39-41 Nitric oxide is the final
common pathway for vasodilatation, once attrib-
uted to an unidentified factor called the endothe-
lial cell-derived relaxing factor. Under normal
physiologic conditions in which hemoglobin is
within the red cell, nitric oxide in the vessel wall
is effective in maintaining vasodilatation and is
Table 3. Hemoglobin-Based Oxygen Carriers
and Hypertension
removed as it dissolves into the plasma and
ultimately attaches to the hemoglobin. When
hemoglobin is free in solution, it appears to
scavenge nitric oxide to a greater extent, thereby
causing vasoconstriction. Because of the limited
clinical experience with these solutions to date, it
is not clear what the magnitude or clinical
significance of the hemodynamic effect will be.
This appears to be a basic characteristic of the
hemoglobin molecule and is one of its physi-
ologic functions. No method has been postu-
lated to modify the stroma-free hemoglobin
solutions to reduce its effect on nitric oxide and
the resulting vasoconstriction. Encapsulation of
the hemoglobin into liposomes may resolve this
issue.
Finally, all hemoglobin solutions interfere
with spectrophotographic laboratory determina-
tions of the concentrations of certain plasma
constituents (D. Giacherio, personal communica-
tion, February 1996). Because of its light-
absorbing quality, plasma hemoglobin, in concen-
trations of approximately 2 g/dL, interferes
significantly with a wide variety of serum chemis-
try determinations. Although other means of
determining these lab values are available, spec-
trophotometric methods are so ubiquitous that
widespread use of the hemoglobin solutions will
require some adaptation.
Despite these limitations, clinical studies are
currently underway to investigate the safety and
efficacy of a variety of hemoglobin solutions. The
advantages and limitations of the oxygen-carry-
ing colloids are listed in Table 4.
In an attempt to address some of the issues
associated with the stroma-free hemoglobin solu-
tions, efforts have been directed to microencap-
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Table 4. Advantages and Limitations of the
Oxygen-Carrying Colloids
sulate hemoglobin. Encapsulation may offer the
following advantages: (1) decrease in the magni-
tude of chemical modification to preserve hemo-
globin function; (2) increase in oxygen-trans-
port capacity by including an allosteric effector;
(3) provide the opportunity to include other
enzymes, such as methemoglobin reductase,
thereby preserving more of hemoglobin’s natu-
ral functions; (4) permit a longer intravascular
half-life through manipulation of capsule
composition and size; and (5) prevent direct
contact of the hemoglobin with blood.39 Gelatin
and polyamide were initially attempted as encap-
sulating proteins, with little success. More re-
cently, liposomes, bimolecular lipid membranes,
have been used.39,42&dquo;5 Hemoglobin liposomes,
variously called hemosomes, liposome-encapsu-
lated hemoglobin, and neo red cells, are able to
carry as much oxygen as an equal amount of
blood, and have a P50 of approximately 40
mmHg at 37’C,45 although maintaining a
lower viscosity.39 Like the stroma-free hemoglo-
bin solutions, liposome-encapsulated heme can
be stored in a frozen or desiccated state, offering
good storage capability. Like the stroma-free
hemoglobin solutions, formation of methemoglo-
binemia remains an issue, but this may be re-
solved by the addition of methemoglobin reduc-
tase to the heme liposome. From the few
laboratory studies performed to date, it appears
that the circulation half-life is similar to that of
stroma-free hemoglobin and fluorocarbons, and
that removal is primarily through the RE system.
It is uncertain whether further developments in
liposome technology will be able to resolve
the chief problem with the proposed blood




The technique of cardiopulmonary bypass re-
sulted in the development of a wide variety of
life-saving cardiac surgeries. It has altered the
expected outcome of nearly every cardiac dis-
ease and dramatically changed the mortality
associated with these disorders. Nonetheless, it is
an assault to the normal homeostasis system. The
exposure of the blood elements to artificial
surfaces, the wide fluctuations in body tempera-
ture, and the addition of large doses of heparin
and protamine all incite an inflammatory re-
sponse that can result in widespread coagulation
abnormalities and reperfusion injury.4648 Addi-
tional injury may occur as the myocardium is
rendered ischemic for a variable length of time.
During this ischemia, the myocardium is pro-
tected by reducing oxygen requirements. Paraly-
sis of the muscle and extreme cooling are the
mainstays of myocardial protection, but at 9°C,
hemoglobin releases little oxygen to the tissues.
The linear relationship between Pa02 and PFC
oxygen content offers a potential advantage
during CPB. Because this relationship is not
affected by decreasing temperature, cardioplegic
solutions that contain PFC could theoretically
provide oxygen delivery during the period of
aortic cross-clamp. Because the P50 of the hemo-
globin solutions is temperature dependent, they
would not be expected to be useful in this
setting. Although there is some laboratory evi-
dence that both the hemoglobin and fluorocar-
bon solutions can ameliorate myocardial or cere-
bral ischemic injury,23>49-53 whether these same
results can be replicated in human patients
remains to be seen.
The blood substitutes may also offer advan-
tages in terms of diminution of the inflammatory
response during the period of cardiopulmonary
bypass. If oxygen delivery during bypass could be
provided with one of the blood substitutes,
theoretically, a significant proportion of the
patient’s blood could be removed and stored to
be transfused at the end of CPB.54 Whether this
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would reduce the inflammatory response to CPB
is also unknown at this time.
Other Blood Substitutes
As alluded to previously, no blood substitute
currently under development does more than
replace the oxygen-carrying function of blood.
Another key function of blood is hemostasis, and
transfusion of plasma and platelets carries the
same infectious and immunomodulatory conse-
quences as do red cell transfusions. The decima-
tion of the factor-deficient population by the
human immunodeficiency virus spurred develop-
ment of recombinant-derived factor VIII and IX,
and the same technology will probably be ap-
plied to all the coagulation factors in the future.
Platelets, with their key role in maintaining
hemostasis, are to date available only as alloge-
neic transfusions, but development of platelet
substitutes has begun. Rybak and Renzullij~ re-
ported on the hemostatic efficacy of a liposome-
based plateletsome. These researchers incorpo-
rated a deoxycholate extract of a platelet
membrane fraction (15 proteins, including GPIb,
GPIIIb-IIIa, and GPIV/III) into lipid-based micro-
vesicles. These plateletsomes decreased rat-tail
bleeding time in thrombocytopenic animals by
67%. Despite the challenges that must be met
before any such platelet substitute is commer-
cially available, these results are promising.
Conclusion
In conclusion, both PFCs and hemoglobin solu-
tions may find useful niches in a variety of
clinical settings in which an oxygen-carrying
drug may benefit a specific organ or clinical
situation. The hemoglobin solutions may be
more useful as field resuscitation fluids before
hospital admission, whereas PFCs may be useful
in an intraoperative setting. Neither of the oxy-
gen-carrying solutions as currently designed will
provide prolonged benefit and may only be
useful to reduce the amount of allogeneic blood
required, not totally replace it. Of course, nei-
ther of these products will benefit or supplement
the coagulation cascade and may actually have a
detrimental effect, at least by dilution. Ulti-
mately, a combination of allogeneic and autolo-
gous blood products, intraoperative and postop-
erative blood salvage techniques, and these
oxygen-carrying solutions may provide an overall
system for reducing mortality, morbidity, and
costs associated with blood transfusions.
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